Ondine Biomedical Inc.
Develops photodisinfection-based therapies to prevent and treat infections.
OBI | TSXV
Overview
Corporate Details
- ISIN(s):
- CA68234M2058
- LEI:
- 9845005B69E07CGF4A56
- Country:
- Canada
- Address:
- SUITE 888 - 1100 MELVILLE ST, V6E 4A6 VANCOUVER
- Website:
- https://ondinebio.com/
- Sector:
- Manufacturing
Description
Ondine Biomedical Inc. is a life sciences company that develops and commercializes photodisinfection-based therapies to prevent and treat a broad spectrum of infections, including those caused by drug-resistant pathogens. The company's patented platform technology involves applying a photosensitive agent to a targeted area, followed by illumination with non-thermal laser light. This process creates an oxidative burst that rapidly destroys pathogens like bacteria, viruses, and fungi without inducing microbial resistance. Its lead product, Steriwave™, is a nasal decolonization therapy used to eradicate pathogens in the nasal cavity, primarily to reduce the risk of healthcare-associated infections (HAIs) such as post-operative surgical site infections. The company's product pipeline is exploring applications for chronic rhinosinusitis, burns, wounds, and ventilator-associated pneumonia.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-08-31 11:49 |
Nature reports Ondine therapy suppresses COVID-19
|
English | 12.4 KB | ||
| 2022-08-16 08:00 |
Ondine appoints RBC and Singer as joint brokers
|
English | 12.6 KB | ||
| 2022-08-08 11:02 |
Ondine completes US Phase II trial recruitment
|
English | 14.4 KB | ||
| 2022-07-26 08:00 |
Completion of Nominated Adviser due diligence
|
English | 9.7 KB | ||
| 2022-07-22 08:00 |
Issue of Equity
|
English | 12.9 KB | ||
| 2022-07-19 08:00 |
Ondine completes successful SARS-CoV-2 trial
|
English | 14.3 KB | ||
| 2022-06-08 08:00 |
Result of AGM
|
English | 12.0 KB | ||
| 2022-06-07 08:00 |
Posting of annual report
|
English | 11.9 KB | ||
| 2022-05-19 08:00 |
Full Year Results to 31 December 2021
|
English | 869.6 KB | ||
| 2022-05-17 08:00 |
Notice of AGM
|
English | 12.5 KB | ||
| 2022-05-10 11:30 |
WHO calls for better infection prevention
|
English | 14.6 KB | ||
| 2022-04-27 17:30 |
Appointment of Nominated Adviser
|
English | 9.5 KB | ||
| 2022-04-05 08:00 |
Photodisinfection effective against SARS-CoV-2
|
English | 9.0 KB | ||
| 2022-02-21 08:00 |
Grant of Options and PDMR Dealing
|
English | 29.4 KB | ||
| 2022-02-07 08:00 |
Ondine treats first patients in Phase 2 FDA trial
|
English | 12.8 KB |
Automate Your Workflow. Get a real-time feed of all Ondine Biomedical Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Ondine Biomedical Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Ondine Biomedical Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
